TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)

NCT04560751 · clinicaltrials.gov ↗

UNKNOWN

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Lenvatinib
PROCEDURE: TACE

Sponsor

Zhejiang Cancer Hospital